Grifols SA
boothcheck covers Grifols SA (GRFS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 27, 2026.
- The valuation methods disagree sharply. The relative and EV/EBITDA methods land far above the $7.39 price near $17 to $26, while the asset-based and earnings-power methods land far below near $1 to $4, leaving the central blended read near $8.32. - The turnaround is in the numbers: first-quarter revenue rose 3.3% at constant currency to roughly €1.7 billion, net profit climbed about 22% to €73 million, and immunoglobulins grew 15.3%, with adjusted EBITDA margin around 22.4%. - The defining con
Is GRFS overvalued? See what's priced in →
182 institutional managers reported holding GRFS in 13F filings for the quarter ended 2026-03-31. Together they hold about 21% of the company; the top 10 hold 16%. 25 opened new positions that quarter. Held by Capital Group (American Funds), Millennium Management, Janus Henderson, among others. On the short side, 6.0M shares were sold short as of the 2026-06-15 count, about 0.9% of shares outstanding (9.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GRFS's share count is about flat over the past five years. It pays a dividend. Cash returned over the past three years: $1.05M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.